- Owns patented Invisicare® polymer delivery system, prescription and over-the-counter skincare products formulated with Invisicare
- Business model to grow globally by out-licensing its proprietary and patented product line
- Developed multiple cannabis-based products with CBD from imported hemp (non-psychoactive), and will continue to develop line utilizing CBD and THC from marijuana
Skinvisible, Inc. (OTCQB: SKVI) is targeting a global skincare market projected to reach $135 billion by 2021 (http://cnw.fm/pE9aT). SKVI also sees a worldwide dermatology market now of $80 billion plus a $30 billion worldwide over-the-counter (OTC) market (http://cnw.fm/NL4we). It has already completed on the development of 40 products, received numerous technology and product patents, and is now ready to monetize its investment. In the US alone, skincare is projected to reach $10.7 billion by 2018 and the global skincare market is seen growing at a compound annual growth rate (CAGR) of 3.8% from 2016-2021 according to MarketResearch.com (http://cnw.fm/46Y2x).
It seeks to maximize profits on already-licensed products and grow by adding more licenses to established manufacturers and marketers. Skinvisible has recently formed commercial subsidiaries, Kintari International Inc., along with Kintari USA Inc. and Kintari Canada, Inc. It formed the subsidiaries to bring its cosmeceutical and select OTC products to market.
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer